Profil
Melissa Lozner is Chief Compliance Officer & Senior Vice President at Regeneron Pharmaceuticals, Inc. since 2022.
Former roles include Chief Compliance & Ethics Officer at Rafael Holdings, Inc. from 2021 to 2022, Attorney at Cravath, Swaine & Moore LLP, and Senior Legal Counsel at Novartis Oncology.
Education includes undergraduate studies at Cornell University and graduate studies at Boston University School of Law.
Aktive Positionen von Melissa Lozner
| Unternehmen | Position | Beginn |
|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Compliance Officer | 01.01.2022 |
Ehemalige bekannte Positionen von Melissa Lozner
| Unternehmen | Position | Ende |
|---|---|---|
| RAFAEL HOLDINGS, INC. | Compliance Officer | 31.01.2022 |
Novartis Oncology | General Counsel | - |
Cravath, Swaine & Moore LLP
Cravath, Swaine & Moore LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Ausbildung von Melissa Lozner
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and commercializes medicines for diseases | Health Technology |
Cravath, Swaine & Moore LLP
Cravath, Swaine & Moore LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boston University School of Law
Boston University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rafael Holdings, Inc.
Rafael Holdings, Inc. Real Estate DevelopmentFinance Operates as holding company with interest in real estate and pharmaceutical sector | Finance |
Novartis Oncology |
















